{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:30:01Z","timestamp":1790325001021,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1097\/cad.0b013e3282f14a00","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T21:28:40Z","timestamp":1236202120000},"page":"1-7","source":"Crossref","is-referenced-by-count":36,"title":["Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer"],"prefix":"10.1097","volume":"19","author":[{"given":"Mary E.R.","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 13","key":"R1-1-20210227","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.seminoncol.2004.09.018","article-title":"The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer","volume":"31","author":"Robert","year":"2004","journal-title":"Semin Oncol"},{"issue":"1","key":"R2-1-20210227","first-page":"3","article-title":"Innovations in anthracycline therapy: overview","volume":"2","author":"Thigpen","year":"2005","journal-title":"Community Oncol"},{"key":"R3-1-20210227","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"R4-1-20210227","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"R5-1-20210227","first-page":"132","article-title":"Clinical measurement in drug evaluation","author":"Praga","year":"1991"},{"key":"R6-1-20210227","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.1998.16.11.3502","article-title":"Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer","volume":"16","author":"Ryberg","year":"1998","journal-title":"J Clin Oncol"},{"key":"R7-1-20210227","first-page":"549","article-title":"Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity [review]","volume":"12","author":"Orditura","year":"2004","journal-title":"Oncol Rep"},{"key":"R8-1-20210227","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"key":"R9-1-20210227","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"key":"R10-1-20210227","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"R11-1-20210227","first-page":"S6","article-title":"Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo","volume":"94","author":"Kim","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"R12-1-20210227","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa054504","article-title":"HER2 and responsiveness of breast cancer to adjuvant chemotherapy","volume":"354","author":"Pritchard","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-1-20210227","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/bcr432","article-title":"Liposome-based drug delivery in breast cancer treatment","volume":"4","author":"Park","year":"2002","journal-title":"Breast Cancer Res"},{"key":"R14-1-20210227","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"R15-1-20210227","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"R16-1-20210227","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2005.03.8331","article-title":"Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial","volume":"24","author":"Chia","year":"2006","journal-title":"J Clin Oncol"},{"key":"R17-1-20210227","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2001.19.14.3439","article-title":"Developing drugs to decrease the toxicity of chemotherapy","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"key":"R19-1-20210227","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial","volume":"15","author":"Ranson","year":"1997","journal-title":"J Clin Oncol"},{"key":"R20-1-20210227","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"R21-1-20210227","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","article-title":"A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)","volume":"42","author":"Coleman","year":"2006","journal-title":"Eur J Cancer"},{"key":"R22-1-20210227","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000093005","article-title":"Reduced incidence of severe palmar\u2013plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40\u2009mg\/m2 every 4 weeks in previously treated patients with metastatic breast cancer","volume":"70","author":"Al-Batran","year":"2006","journal-title":"Oncology"},{"key":"R23-1-20210227","first-page":"441","article-title":"Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure","volume":"27","author":"Mlineritsch","year":"2004","journal-title":"Onkologie"},{"key":"R24-1-20210227","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.bjc.6603158","article-title":"The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial","volume":"94","author":"Al-Batran","year":"2006","journal-title":"Br J Cancer"},{"key":"R25-1-20210227","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00280-001-0405-3","article-title":"Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer","volume":"49","author":"Rivera","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"R26-1-20210227","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1634\/theoncologist.10-3-205","article-title":"Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer","volume":"10","author":"Rose","year":"2005","journal-title":"Oncologist"},{"key":"R27-1-20210227","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"R29-1-20210227","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R30-1-20210227","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/jco.2007.25.18_suppl.1007","article-title":"Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study","volume":"25","author":"Alba","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"R31-1-20210227","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin Oncol"},{"key":"R32-1-20210227","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00685327","article-title":"Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin","volume":"33","author":"Conley","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"R33-1-20210227","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminoncol.2004.08.002","article-title":"Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies","volume":"31","author":"Vail","year":"2004","journal-title":"Semin Oncol"},{"key":"R34-1-20210227","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R35-1-20210227","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","article-title":"Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes","volume":"86","author":"Symon","year":"1999","journal-title":"Cancer"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e3282f14a00","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:45:09Z","timestamp":1786038309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200801000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3282f14a00","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}